Pharmaceutical Executive-07-01-2021

With small biotechs facing similar expectations as large pharma in drug safety and pharmacovigilance, despite less resources, identifying the key differences between US and EU requirements can help these companies craft a practical path to multi-region compliance.

Seeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.

Latino executives share their experiences and insights on the community’s contributions to the life sciences industry.

Along with the industry’s massive effort to tackle the health and social problems exposed by COVID, pharma companies have spent the last year addressing the internal impact of racial inequalities following the murder of George Floyd.

Influenced by lessons from the playing field, former rugby athlete James Robinson, today president and CEO of Urovant Sciences, discusses the keys to establishing a high-performing team culture in biopharma—and the end-game wins in treatment gain and patient need.

A remarkable run indeed, but cost questions can’t be ignored.

Closing the gaps in complex therapy data remains a hurdle, but “getting clever” with AI can offer a path forward.

Give your team members opportunities to lead for greater growth.

Summits, proposals outline advice on response to future pandemics.

White House backs big boost in funding for research, public health.

Looking back at 2000-2002.

Recent roundtable highlights need for biopharma to enter ESG conversation.

Debate on origin of virus responsible for global pandemic continues on.

Click the title above for a link to open the Pharmaceutical Executive July 2021 issue in an interactive PDF format.

Commercial-model shift demanding greater influence of these teams.

The eight key areas biopharma manufacturers must stay on top of when planning and executing alliance agreements with prospective digital health partners.